Mepivacaine 2% with epinephrine 1:100,000 — Competitive Intelligence Brief

Mepivacaine 2% with epinephrine 1:100,000 (Mepivacaine 2% with epinephrine 1:100,000) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic. Area: Anesthesiology.

phase 3 Local anesthetic Voltage-gated sodium channels Anesthesiology Small molecule

Target snapshot

Mepivacaine 2% with epinephrine 1:100,000 (Mepivacaine 2% with epinephrine 1:100,000) — Qassim Health Cluster. Mepivacaine is a local anesthetic that blocks sodium channels to prevent nerve impulses, while epinephrine constricts blood vessels to prolong the anesthetic effect.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Mepivacaine 2% with epinephrine 1:100,000 TARGET	Mepivacaine 2% with epinephrine 1:100,000	Qassim Health Cluster	phase 3	Local anesthetic	Voltage-gated sodium channels
Lidocaine alone	Lidocaine alone	TriHealth Inc.	marketed	Local anesthetic	Voltage-gated sodium channels
Isobaric bupivacaine 0.5%	Isobaric bupivacaine 0.5%	Hospital Clínico Universitario de Valencia	marketed	Local anesthetic (amide class)	Voltage-gated sodium channels
IV Lidocaine	IV Lidocaine	University of Washington	marketed	Local anesthetic / Antiarrhythmic agent (Class IB)	Voltage-gated sodium channels
Hydrocortisone acetate and lidocaine hydrochloride	Hydrocortisone acetate and lidocaine hydrochloride	Citius Pharmaceuticals, Inc.	marketed	Topical corticosteroid and local anesthetic combination	Glucocorticoid receptor (hydrocortisone); voltage-gated sodium channels (lidocaine)
Lidocaïne	Lidocaïne	University Hospital, Angers	marketed	Local anesthetic	Voltage-gated sodium channels
lidocaine and sufentanil	lidocaine and sufentanil	RenJi Hospital	marketed	Local anesthetic and opioid analgesic combination	Voltage-gated sodium channels (lidocaine); mu opioid receptor (sufentanil)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic class)

1. University of California, San Diego · 3 drugs in this class
2. Durect · 3 drugs in this class
3. Pacira Pharmaceuticals, Inc · 3 drugs in this class
4. Wake Forest University Health Sciences · 3 drugs in this class
5. Medical University of Vienna · 3 drugs in this class
6. Imperial College London · 2 drugs in this class
7. Hvidovre University Hospital · 2 drugs in this class
8. Innocoll · 2 drugs in this class
9. George Washington University · 2 drugs in this class
10. Guy's and St Thomas' NHS Foundation Trust · 2 drugs in this class